Susan J. Schniepp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Susan J. Schniepp


Susan J. Schniepp is a Pharmtech editorial advisory board (EAB) member

Susan J. Schniepp
Vice-President, OSO Biopharmaceuticals

Susan Schniepp has more than 28 years of experience in quality assurance for both the food and pharmaceutical industries. She has a degree in microbiology from Northern Illinois University and began her career in 1980 as a microbiologist in the food industry for Quaker Oats and M&M/Mars. In 1984, she began working for Searle Pharmaceuticals, and in 2000 she began working for Abbott Laboratories. In 2007, she formed her own consulting firm specializing in training, quality systems, technical writing, and standards interpretations. During her career in industry she had responsibilities for complaints, labeling, validation, documentation, and other quality systems, with a primary focus on establishing communications with compendial authorities.

Schniepp joined PDA in 2000 when she began working for Abbott Laboratories. She has presented at a number of PDA meetings and participated on a number of committees including the Joint Regulatory Conference Steering Committee, RAQC, Program Advisory Board, Technical Books Advisory Board, and The Membership Committee. In 2007, she was the recipient of PDA’s Distinguished Author Award for Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.

In addition to her PDA activities, Schniepp is chair of USP’s Monograph Development – Psychiatrics and Psychoactives Expert Committee for the 2005–2010 revision cycle, in addition to serving on the Council of Experts Executive Committee from 2005–2007. She is active in the Generic Pharmaceutical Association and founded both the Midwest and Western Compendial Discussion Groups.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here